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Background: Data from next generation sequencing technologies uncovered the existence of many classes of
small RNAs. Recent studies reported that small RNAs are released by cells and can be detected in the blood. In this
report, we aimed to discover the occurrence of novel circulating small RNAs in coronary artery disease (CAD).
Methods: We used high-throughput sequencing of small RNAs from human and mouse apoptotic primary
macrophages, and analyzed the data by empirical Bayes moderated t-statistics to assess differential expression
and the Benjamini and Hochberg method to control the false discovery rate. Results were then confirmed by
Northern blot and RT-qPCR in foam cells and in two animal models for atherosclerosis, namely ApoE−/− and
Ldlr−/− mouse lines. Quantitative RT-PCR to detect identified small RNAs, the RNY-derived small RNAs, was
performed using sera of 263 patients with CAD compared to 514 matched healthy controls; the Student t-test
was applied to statistically assess differences. Associations of small RNAs with clinical characteristics and biological
markers were tested using Spearman’s rank correlations, while multivariate logistic regressions were performed to test
the statistical association of small RNA levels with CAD.
Results: Here, we report that, in macrophages stimulated with pro-apoptotic or pro-atherogenic stimuli, the
Ro-associated non-coding RNAs, called RNYs or Y-RNAs, are processed into small RNAs (~24–34 nt) referred to
as small-RNYs (s-RNYs), including s-RNY1-5p processed from RNY1. A significant upregulation of s-RNY expression was
found in aortic arches and blood plasma from ApoE−/− and Ldlr−/− mice and in serum from CAD patients (P <0.001).
Biostatistical analysis revealed a positive association of s-RNY1-5p with hs-CRP and ApoB levels; however, no statistical
interaction was found between either of these two markers and s-RNY1-5p in relation to the CAD status. Levels
of s-RNY1-5p were also independent from statin and fibrate therapies.
Conclusion: Our results position the s-RNY1-5p as a relevant novel independent diagnostic biomarker for
atherosclerosis-related diseases. Measurement of circulating s-RNY expression would be a valuable companion
diagnostic to monitor foam cell apoptosis during atherosclerosis pathogenesis and to evaluate patient’s
responsiveness to future therapeutic strategies aiming to attenuate apoptosis in foam cells in advanced
atherosclerotic lesions.
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There are several classes of small RNAs, including
microRNAs, siRNAs, piRNAs, and those derived from
sno-RNAs, tRNAs, or Alu repeats. Significant amounts
of microRNAs have been recently found in extracellular
body fluids such as blood, urine, saliva, and semen [1].
Some circulating microRNAs in the blood have been
proposed as biomarkers for several human disorders,
including cardiovascular diseases [1, 2].
In this report, we have explored whether pro-apoptotic
stimuli regulate the expression of novel small RNAs in
macrophages using a high-throughput sequencing ap-
proach. Macrophage apoptosis is a tightly-regulated
mechanism that controls tissue homeostasis and can be
induced by a variety of signals and stress factors, includ-
ing bacterial toxins, DNA damage, oxidant stress, endo-
plasmic reticulum (ER) stressors, cytokines, activation of
Fas death pathway, modified low-density lipoprotein
(LDL) such as oxidized LDL (oxLDL) or acetylated LDL
(acLDL), and saturated fatty acids [3, 4]. Its physiopatho-
logical importance is highlighted by the fact that apop-
tosis in macrophages is involved in many inflammatory
diseases, including atherosclerosis [4]. In particular, in-
duction of macrophage apoptosis accelerates the devel-
opment of atherosclerosis in advanced atherosclerotic
lesions [5, 6].
A key initiating step of atherogenesis is the suben-
dothelial accumulation of apolipoprotein B (apoB)-
containing lipoproteins (apoB-LPs), mainly composed
by LDL [7]. The modification of LDL lipid content
triggers a low-grade inflammatory response leading to
activation of endothelial and vascular smooth muscle
cells (SMCs) and recruitment of monocytes and
monocyte-derived macrophages, which play a major
and dual role in atherosclerosis pathogenesis [4]. In
fact, in early phases, macrophages engulf LDL and
modified LDL, becoming lipid-laden macrophages –
so-called foam cells, which secrete inflammatory cyto-
kines and undergo apoptosis. Rapid efferocytic clearance
of apoptotic foam cells leads to a decrease of the inflam-
matory response and retards atherosclerosis progression
[8]. However, in advanced atherosclerotic lesions, macro-
phage apoptosis is not properly coupled with phagocytic
clearance, leading to an upregulation of inflammation and
to necrotic plaque formation [9]. This may ultimately lead
to clinical events such as heart attack or stroke [10].
Atherosclerosis is responsible for cardiovascular dis-
eases, including coronary artery disease (CAD), per-
ipheral vascular diseases, and strokes, which are now
considered to be the single largest scourge of modern
society [10]. CAD occurs when atherosclerosis affects
the heart arteries. According to the World Health
Organization, in 2008, nearly 30 % of deaths worldwide
were attributed to cardiovascular diseases, which arepredicted to become the greatest single-disease cause of
death at a global scale by 2030 [11]. This will ultimately
lead to an increase in direct and indirect costs in the
treatment of CAD patients, which was estimated to be
about $ 165 billion in the United States alone in 2009
[11]. Although assessment of classic cardiovascular risk
factors or markers, including high blood pressure, dia-
betes, smoking, and high LDL-cholesterol, has had a
central role in disease prevention and therapeutic
choice, the need of novel diagnostic biomarkers for
atherosclerosis is underlined by the fact that even the
reduction of classical risk factor and/or marker levels,
such as LDL-cholesterol, does not fully prevent coron-
ary events, which still occur at high rates [12]. In
addition, a great clinical need exists for biomarkers for
risk stratification to restrict current therapies to pa-
tients at greatest risk of clinical events, who most
likely will benefit the most. On the other hand, it
would reduce side effects and unnecessary costs among
patients at low risk, for whom the benefit-risk balance of
therapies is less favorable [7].
Herein, we demonstrate that the ~110 nucleotide (nt)
long Ro-associated non-coding RNAs, termed RNYs, are
processed into small 24–34 nt sequences in macro-
phages upon pro-apoptotic or pro-atherogenic treat-
ments. The expression of RNY-derived small RNAs is
significantly upregulated in two mouse models for ath-
erosclerosis and in the serum of CAD patients. Our data
indicate that RNY-derived small RNAs can be used as
novel independent biomarkers, related to apoptosis of
lesional macrophages, well suited for the assessment of
CAD risk or in the setting of future therapeutic strat-
egies aiming to attenuate macrophage apoptosis in ad-
vanced atherosclerotic lesions.
Methods
Small RNA sequencing: experimental design
Human primary macrophages were treated with 1 μM
staurosporine (STS) for 4 or 6 h, whereas mouse bone
marrow-derived macrophages (BMDMs) were incubated
in a Macrophage-Colony Stimulating Factor (M-CSF)
withdrawal conditioned medium for 36 h. We then ex-
tracted total RNA from treated and untreated cells using
RNA columns (miRNeasy, Qiagen). The RNA quality
was checked on a bioanalyzer with the RNA 6000 Nano
kit (Agilent Technologies). Two small RNA sequencing
runs were performed. In the first, 1.5 μg of total RNA
from one biological replicate for each condition were
subjected to small RNA library preparations using the
NEBNext Small RNA Library Prep Set for SOLID™ kit
(New England Biolabs), following the manufacturer’s in-
structions. Libraries were then sequenced on a SOLiD
5500 platform (Life Technologies) with a 35-bp fragment
length. For the second run, 50 ng of total RNA from two
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small RNA library preparation with the CleanTag library
kit (TriLink Biotechnologies) following the manufac-
turer’s instructions. These libraries were sequenced on
an Ion Proton PI Chip (Life Technologies).
Two NEBNext Small RNA libraries were also made
from 25–40 nt size selected RNA purified by polyacryl-
amide gel electrophoresis from M-CSF withdrawal-
treated mouse macrophages and control, and sequenced
with SOLiD 5500 platform to control the presence of
cleaved forms of RNYs.
Small RNA sequencing: data analysis
Fragments that were sequenced with SOLiD run were
mapped on hg19 for human samples and mm10 for mice
samples within LifeScope 2.5.1 small RNA pipeline (Life
Technologies) with default parameters; .bam files were
then merged with MergeSamFiles.jar (picard-tools-1.38)
for each sample, keeping a read group per lane. Frag-
ments that were sequenced with Ion Proton P1 Chip
were first trimmed with cutadapt v1.2.1 for 5p adapter
TTCTACAGTCCGACGATC and 3p adapter TGGA
ATTCTCGGGTGCCAAGG. Reads with size <15 bases
were discarded. Remaining reads were mapped to hg19
build for human samples and mm10 build for mouse sam-
ples with bowtie2 (v2.2.4) with “–local –very-sensitive-
local -k 10”. All .bam files were processed with a java
homemade class, based on Picard java classes to iden-
tify and quantify small RNAs. Annotation files used
for quantification correspond to miRbase release 21,
tRNAs from UCSC web server (UCSC tables), RNYs
and ncRNAs from ensembl ncRNAs release 75, and
piRNAs from fRNAdb.
All sequencing results were submitted to the GEO
database under the superseries accession number
GSE63802.
For quantitative analysis of small RNAs, each count
data table generated from SOLiD and Ion Proton experi-
ments was merged based on feature IDs. When the sum
of reads mapped on each gene was less than five reads
in a specific experiment, they were discarded (low
level of expression). The final datasets comprised
1,338 genes for mouse data and 1,435 genes for hu-
man data. Functions from the Bioconductor package
limma [13] were used to normalize data and assess
differential expression.
For statistical analysis, count data were first normal-
ized for sequencing depth differences and transformed
into log2 count per million using the voom function [14]
and differential expression was assessed using linear
modeling. For each gene, a linear model was fit with
two parameters, one for the comparison of interest
(treatment vs. control) and one to account for poten-
tial technology bias between the two runs. EmpiricalBayes moderated t-statistics were used to assess dif-
ferential expression. The Benjamini and Hochberg
method was used to control the false discovery rate [15],
for which a value <0.05 was considered significant.
Animals and diets
The following mice were purchased from Charles River
Laboratories (L’Arbresle, France): C57BL/6 J, ApoE−/−
(B6.129P2-APOE/J), and Ldlr−/− (B6.129S7-Ldlrtm1Her/J).
High cholesterol diet (HCD) formula # TD02028 (1.3 %
of cholesterol) and TD96335 (1.25 % of cholesterol) for
ApoE−/− and Ldlr−/−, respectively, were purchased from
ssniff Spezialdiaten GmbH (Soest, Germany). ApoE−/−
and Ldlr−/− male mice at 8 weeks of age were fed
with either HCD or regular diet (chow diet) for 12
and 20 weeks, respectively. Aortic arches, femoral ar-
teries, and blood plasma were dissected. CD68-hBcl-2
ApoE−/− was generated as previously described [5].
Blood plasma of mice fed with chow diet was collected at
the age of 27–30 weeks.
Reagents
Lipoteichoic acid from the Gram-positive bacteria
Staphylococcus aureus, thapsigargin (Tg), STS, bo-
vine serum albumin, palmitic acid, stearic acid, oleic
acid, linoleic acid, fluvastatin, simvastatin, lovastatin,
and pravastatin were purchased from Sigma (Saint-
Quentin Fallavier, France). oxLDL was purchased from
Clinisciences (Nanterre, France). LDL was isolated from
the plasma of normolipidemic healthy human donors by
standard sequential ultracentrifugation of discontinuous
KBr gradients. LDL were acetylated (acLDL) by addition
of 1.5 μL acetic anhydride per milligram of LDL in 50 %
ice-cold saturated sodium acetate over a 1-hour period at
4 °C. The acLDL was dialyzed against 150 mM NaCl,
5 mM Tris–HCl, and 0.3 mM EDTA, pH 7.4 at 4 °C
and gave a single band on agarose electrophoresis.
Anti-Ro60 (TROVE2) and anti-Argonaute 2 antibodies
were purchased from GmbH and Wako, respectively.
Primary cells and cell lines
Bone marrow cells were collected from femurs and
tibias of 10-week-old male C57BL/6 J mice by flush-
ing with sterile medium as previously described [16].
To differentiate into macrophages, bone marrow cells
(×106) were plated in 10-cm plates in 7 mL of
BMDM medium (Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 20 % low-endotoxin fetal
bovine serum, 30 % L929-cell conditioned medium, 1 %
l-glutamine, 1 % Pen/Strep, 0.5 % Na pyruvate, and 0.1 %
β-mercaptoethanol), and fed with 2.5 mL of fresh medium
every two days for 7 days. Human primary macrophages
were prepared from peripheral blood monocytes obtained
from healthy donors [17] in agreement with the French
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provided written informed consent attesting they had re-
ceived all the information required about the study and
they agreed to its publication in accordance with appro-
priate national regulations).
Mouse aortic vascular smooth muscle cells (ATCC®
CRL-2797 cell line) and murine endothelial cells (ATCC®
CRL 2181 cell line) were seeded in six-well plates (2 × 106
and 2 × 105 cells/mL, respectively) and grown in DMEM,
high glucose, GlutaMAX™ (Life Technologies) with 10 %
heat-inactivated fetal bovine serum, 100 IU/mL penicillin,
and 100 μg/mL streptomycin (Life Technologies).
Adult ventricular myocytes were obtained from the
heart of C57/BL6 male mice at 8 weeks of age with
retrograde perfusion as previously described [18]. The cell
pellet was resuspended in DMEM containing 2 mg/mL
bovine serum albumin, 2 mmol/L l-carnitine, 5 mmol/L
creatine, 5 mmol/L taurine, 100 IU/mL penicillin, and
100 μg/mL streptomycin. Isolated myocytes were then
seeded onto gelatin-coated six-well plates (1 × 106
cells/mL) in Ham-F12 medium supplemented with 3 %
fetal bovine serum.
Cell transfection and RNA immunoprecipitation
BMDMs were transiently transfected for 48 h with
Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. 2′-O-Me-RNA antisense
oligonucleotides to s-RNYs (Eurogentec) were trans-
fected at the final concentration of 100 nM. A total
of 300 μg of proteins was immunoprecipitated with
Protein A-Dynabeads-coupled (Invitrogen) antibodies
for 16 h at 4 °C with rotation. Immunoprecipitated pellets
were washed four times with lysis buffer and resuspended
in Trizol (Invitrogen), then analyzed by RT-qPCR. The
primer sequences are detailed in Additional file 1:
Table S6.
Northern blot
Total RNA was isolated from cells using Trizol
(Invitrogen), resolved on 10 % polyacrylamide-urea
gels, and electroblotted onto HyBond N+ membranes.
Membranes were hybridized overnight with radiola-
beled DNA antisense oligonucleotides to s-RNYs in
ExpressHyb solution (Clontech). After hybridization,
membranes were washed three times with 2× SSC
and 0.05 % SDS, twice with 0.1× SSC and 0.1 % SDS,
and exposed overnight onto a film. The same blot
was hybridized (upon stripping in boiling 0.1 % SDS)
up to three distinct probes, including control U6 snRNA
(Additional file 1: Table S6).
s-RNY expression analysis and cloning
For s-RNYs detection by quantitative RT-PCR we used
the stem-loop quantitative RT-PCR method previouslydescribed by Chen et al. [19]. This method allows the
detection of only s-RNYs derived from the 5′ end of the
precursor by quantitative RT-PCR analysis, namely the
s-RNY1-5p and s-RNY3-5p from mouse and s-RNY1-
5p, s-RNY3-5p, and s-RNY4-5p from human. Briefly,
total RNA was isolated from cells, tissue, or immunopre-
cipitation using Trizol (Invitrogen) according to the
manufacturer’s instructions.
RNA extraction from extracellular medium, blood
plasma, and serum was performed as previously de-
scribed [1]. Briefly, before the extraction of RNA, we
checked hemolysis by spectrophotometrically measuring
oxyhemoglobin at 414 nm and referring to a standard
curve made by introducing hemolysis by serially diluting
lysed red blood cells in non-hemolysed plasma from a
healthy donor [20]. The serum samples showing an op-
tical density corresponding to more than 0.002 % of red
blood cells (v/v) were discarded. Then, 0.6 mL of Trizol
LS were added to 0.2 mL of blood plasma, serum, or
media. Following this, (1) 5 pg of synthetic miRNA-39
from Caenorhabditis elegans (cel-miR-39) were added as
a spike-in control for purification efficiency and (2) 1.2 μL
of glycogen (10 mg/mL) were added to enhance the effi-
ciency of RNA column binding. Purification of extracted
total RNA was performed with miRNeasy columns
(Qiagen) according to the manufacturer’s instructions.
RNA was eluted in 30 μL of RNase-free water and sub-
jected to on-column DNase I treatment with RNase-free
DNase (Qiagen). The quality of the extracted RNA was
checked by ratio between the absorbance values at 260
and 280 nm and between 260 and 230 nm using a
NanoDrop Technologies ND-1000 spectrophotometer.
As cell-free RNA, such as that from serum or the extra-
cellular milieu, does not contain any ribosomal RNAs,
we therefore checked the presence of ribosomal RNAs
in some samples by pico total RNA bioanalyzer (Agilent)
as a sign of cellular contamination.
Reverse transcriptase reaction was performed accord-
ing to Chen et al. [19] for the detection of s-RNYs, n-code
(Life Technologies) for RNU48, and TaqMan (Life
Technologies) for the miRNAs. Quantitative RT-PCRs
using Sybr Green or TaqMan (Invitrogen) for s-RNYs,
cel-miR-39, miR-24, miR-17, miR-92a, miR-126, miR-133,
miR-145, miR-155, RNU48, and miR-208 were performed
on a StepONE system (Applied Biosystem). Expression
was considered undetectable with Ct value ≥40. The target
small RNA expression value was normalized with a
reference gene: the exogenous spike-in cel-miR-39, or
the endogenous hsa-miR-24 [21] or RNU48 [22], as
indicated in the respective legends. The relative ex-
pression level of s-RNYs was then further normalized
by the 2-ΔΔCt method. The Student t-test was per-
formed to assess statistical significance. The primer
sequences are detailed in Additional file 1: Table S6.
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were indeed derived from RNYs, we immunoprecipitated
Ro60 with an anti-Ro60 antibody followed by RT-qPCR
(Additional file 2: Figure S3D), showed that there was a
lack of signal in palmitic acid-treated macrophages
transfected with 2′-O-Me-RNA antisense oligonucleo-
tides to s-RNYs (Additional file 3: Figure S5A), and
cloned the RT-PCR products from CAD patients in
pCR4-TOPO vector according to the manufacturer’s in-
structions (Additional file 3: Figure S5B; other data not
shown). Altogether, these data indicate that the s-RNYs
detected were indeed derived from RNYs.
Study sample
The Génétique et Environnement en Europe du Sud
(GENES) study is a case–control study designed to
investigate the role of genetic, biological, and environ-
mental determinants in the occurrence of CAD. As
previously described [23, 24], cases were stable CAD
patients, aged 45–74, living in the Toulouse area
(southwest France) and prospectively recruited from 2001
to 2004 after admission to the Cardiology Department,
Toulouse University Hospital, for cardiovascular examin-
ation and referred for evaluation and management of their
CAD. Stable CAD was defined by a previous history of
acute coronary syndrome, a previous history of coronary
artery revascularization, a documented myocardial is-
chemia, a stable angina, or the presence at coronary
angiography of a coronary stenosis of 50 % or more.
Patients who had presented an acute coronary episode
during the past 8 days were not included in the
study, because they were considered unstable. During
the same period, male controls, aged 45–74, were se-
lected from the general population using electoral
rolls. Stratification into decadal age groups was used
to approximately match the age distribution of the
people with and without CAD.
In the present study, s-RNY1-5p expression was ana-
lyzed in 263 randomly selected CAD patients from the
initial sample; 514 control subjects were frequency-
matched to the cases with respect to age in a 2:1 ratio.
This cohort was subsequently randomly divided into one
derivation sub-cohort of 43 CAD patients and 106 con-
trols, and one validation sub-cohort of 220 CAD patients
and 408 controls. Male controls underwent medical
examination in the same health center administered by
the national health insurance system, located approxi-
mately in the center of the study area. Similarly, male
cases were examined at the Department of Cardiology,
Toulouse University Hospital, over the same period.
Inclusion commenced after the provision of oral and
written information about the aim of the study,
followed by the signing of informed consent. The
medical examination took approximately 120 minutes.Medical examination included clinical and anthropo-
metric measurements and was followed by the com-
pletion of a questionnaire (lasting for approximately
40 minutes). Blood samples were taken and a blood
sample collection was constituted.
Serum was collected from 17 male individuals infected
from different portal of entries (lung, bone, cutaneous,
digestive, urinary tract) by various bacteria (Additional
file 4: Table S5). No clinical evidence of atherosclerotic
lesions was reported on this cohort. s-RNY1-5p and high
sensitive C-reactive protein (hs-CRP) expression was
measured and compared to 35 age-matched controls
from the GENES study.
Data collection
Male participants with and without CAD were examined
in the morning after an overnight fast. Patients with
stable CAD (cases) were examined in the clinics of the
Cardiology Department, Toulouse University Hospital,
and underwent a coronary angiography. Control subjects
were examined in the same health center. The medical
examination started with standardized face-to-face
interviews performed by a trained physician using stan-
dardized methods. During this interview, participants re-
ceived oral and written information on the aim of the
study and signed a consent form. Then, a blood sample
was taken from each participant. Each participant then
completed standardized questionnaires, covering age,
socioeconomic variables, educational level (number of
years spent at school), smoking status, alcohol consump-
tion, physical activity, information on cardiovascular risk
factors, and past medical (personal and parental) history.
The medical examination was continued with anthropo-
metric and clinical measurements. Tobacco consump-
tion was expressed in pack-year by multiplying the
number of packs of cigarettes smoked per day by the
number of years the person had smoked. Alcohol con-
sumption was assessed using typical weekly patterns.
Physical activity was investigated through a standardized
questionnaire [25] and categorized into three levels: no
physical activity; moderate physical activity, over 20 mi-
nutes no more than once a week; and high physical
activity, over 20 minutes, at least twice a week. Presence
of dyslipidemia, diabetes, or hypertension was assessed
from the subjects’ current treatments. In those with
CAD, their medication at discharge was also considered.
Anthropometrical measurements included waist circum-
ference and body mass index (BMI). Blood pressure and
heart rate were measured with an automatic sphygmo-
manometer. Right arm blood pressure was measured
twice, and the average value was recorded. Measure-
ments were performed after a 5 min rest. The ankle-
arm index was determined as previously described,
and a value ≤0.9 was considered abnormal [26]. Blood







Age (years) 60.3 (8.0) 59.0 (8.3) 0.04
Education (years of schooling) 9.6 (3.0) 13.1 (4.3) 0.001 a
Alcohol (g/day) 28.8 (28.5) 23.8 (24.1) 0.09 a
Tobacco consumption number
(pack/year)
41.5 (37.9) 17.2 (21.3) 0.001 a




Waist (cm) 99.3 (10.7) 95.3 (9.9) 0.001
Body mass index (kg/m2) 27.5 (4.0) 26.9 (3.6) 0.04
Total cholesterol (g/L) 2.02 (0.38) 2.24 (0.38) 0.001
HDL-cholesterol (g/L) 0.43 (0.12) 0.55 (0.13) 0.001
LDL-cholesterol (g/L) 1.25 (0.34) 1.45 (0.32) 0.001
Triglyceride (g/L) 1.68 (0.89) 1.21 (0.77) 0.001 b
ApoA-I (g/L) 1.23 (0.22) 1.50 (0.24) 0.001
ApoB (g/L) 1.04 (0.22) 1.08 (0.22) 0.03
Lipoprotein (a) (g/L) 0.47 (0.44) 0.30 (0.37) 0.001 b
hs-CRP (mg/L) 17.2 (29.7) 3.1 (5.1) 0.001 a
Gamma glutamyl transferase
(IU/L)
62.8 (68.6) 45.2 (56.8) 0.001 a
Fasting glucose (mmol/L) 5.93 (2.01) 5.43 (1.06) 0.19 a
Serum insulin (UI/L) 15.9 (19.5) 10.0 (8.1) 0.001 a




Systolic blood pressure (mmHg) 137.0 (20.2) 137.4 (16.5) 0.82 a
Resting heart rate (beat/mn) 63.7 (11.5) 62.8 (9.2) 0.79 a
Ankle-arm index ≤0.9 (%) 33.6 1.6 0.001
Treatment for hypertension (%) 44.1 19.6 0.001
Treatment for diabetes (%) 23.2 5.2 0.001
Treatment for dyslipidemia (%) 63.5 23.3 0.001
s-RNY1-5p 10.42 (12.33) 1.32 (1.67) 0.001 a
(RNY1-5p)1/7 1.33 (0.18) 0.95 (0.19) 0.001
Quartiles RNY1-5p (%) 0.001
Q1 : <0.47 0.4 37.9
Q2 : 0.47–1.62 5.3 34.6
Q3 : 1.61–4.70 28.5 23.4
Q4 : >4.70 65.8 4.1
Data are expressed as mean (±SD) or percentage (%)
a Wilcoxon–Mann–Whitney test
b Analyses performed on log transformed data
ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; hs-CRP, High sensitive
C-reactive protein; HOMA-IR, Homeostatic model assessment-insulin resistance;
NCEP ATP-III, National Cholesterol Education Program’s Adult Treatment Panel
III report
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cholesterol, triglycerides, glucose, γ-glutamyltransferase,
and hs-CRP with enzymatic reagents on an automated
analyzer (Hitachi 912, Roche Diagnostics, Meylan,
France). Apolipoprotein A-I (ApoA-I), ApoB, and lipopro-
tein (a) were assayed with an immunoturbidimetric
method on an automated analyzer (Roche Diagnostics,
France). LDL-cholesterol was calculated using the
Friedewald formula, with very LDL-cholesterol (g/L) =
triglycerides (g/L)/5, as long as triglyceride concentra-
tion was below 4 g/L [27]. Among metabolic markers,
total or LDL- cholesterol were lower in CAD individ-
uals, probably reflecting effects of lipid-lowering drugs
in patients (Table 1).
Statistical analysis
Continuous variables were displayed as means and
standard deviations. Categorical variables are presented
as proportions. In univariate analyses, qualitative vari-
ables were compared with χ2 test (or Fisher exact test
when necessary). Mean values of quantitative variables
were compared by the Student t-test. The Shapiro–
Wilks and the Levene tests were used to test the nor-
mality of distribution of residuals and the homogeneity
of variances, respectively. When basic assumptions of
the Student t-test were not satisfied, a logarithmic trans-
formation of the variables was done or the Wilcoxon–
Mann–Whitney test was performed. A seventh root
transformation of s-RNY1-5p was made to approximate
normal distribution of the variable (Additional file 5:
Figure S4B and C). In cases and controls groups, associ-
ations of s-RNY1-5p with clinical characteristics and
biological markers were tested using Spearman’s rank
correlations.
Multivariate logistic regressions were carried out to
test the statistical association of s-RNY1-5p levels with
CAD. Analyses were performed firstly without adjust-
ment and secondly after adjustment on classical cardio-
vascular risk factors, without any specific selection. The
following cardiovascular risk factors were introduced
in the model a priori: waist circumference, tobacco
consumption (pack/year), total alcohol consumption,
hs-CRP, apoA-I, apoB, hypertension (defined as sys-
tolic blood pressure >160 mmHg or diastolic blood
pressure >95 mmHg or antihypertensive medication),
diabetes (defined as blood glucose >7.8 mmol/L or
anti-diabetic medication), statin drug, fibrate drug, and
ankle-arm index, a clinical marker of peripheral arterial
disease. Model assumptions were verified. Since the lin-
earity of the relationship between s-RNY1-5p and the
dependent variable (CAD status) was not verified, we
performed analyses using quartiles of s-RNY1-5p. In
these models, higher levels of s-RNY1-5p were strongly
and significantly associated with CAD. The performance
Fig. 1 (See legend on next page.)
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Fig. 1 Apoptotic and atherogenic stimuli induce s-RNY expression in macrophages. a MA plot distribution from the high throughput sequencing
analysis of differentially expressed small RNAs in human primary macrophages stimulated with 1 μM of staurosporine (STS) for 6 hours compared to
control. Green dots indicated RNYs. b Northern blot detecting the indicated s-RNYs in apoptotic mouse bone marrow-derived macrophages (BMDMs)
upon 36 h of M-CSF withdrawal treatment or reconstitution after 12 h of starvation. U6 snRNA was used as loading control. CTL indicates
control. c RT-qPCR analysis of the indicated s-RNYs in mouse BMDMs incubated for 28 h with 0.25 μM of thapsigargin (Tg) alone or in
combination with the indicated concentrations of oxidized LDL. The data were normalized by U2 snRNA and presented as mean and standard
deviation (n per group = 8). d RT-qPCR analysis of the indicated s-RNYs in mouse BMDMs incubated for 18 h with 0.25 μM of Tg with bovine
serum albumin (BSA), 0.25 mM of the indicated fatty acids in complex with BSA, or Tg plus the fatty acids. The data were normalized by U2
snRNA and presented as mean and standard deviation (n per group = 8). The unsaturated fatty acids were linoleic acid (LA) and oleic acid (OA),
and the saturated fatty acids were stearic acid (SA) and palmitic acid (PA). RT-qPCR analysis of the indicated s-RNYs in control and ApoE−/− (e) or
Ldlr−/− (f) aortic arches. The mice were fed with either chow diet or high cholesterol diet. The data were normalized by U2 snRNA and presented
as mean and standard deviation (n per group = 8 for (e) and n per group = 5 for (f)). Student’s t-test: *P <0.05; **P <0.01
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under the receiver operating characteristic (ROC) curve
(AUC). The internal validity of the prediction model
was evaluated by bootstrapping [28] using 100 random
samples (not shown). ROC curves were constructed,
and models with and without s-RNY1-5p, were com-
pared [29]. Analyses were two-tailed, and P <0.05 was
considered to be significant.
Ethics, permissions, and consent
Written informed consent was obtained from all partici-
pants involved in the study, including publication agree-
ment. Biological collection was constituted according to
the principles expressed in the Declaration of Helsinki
and registered under number DC-2008-403 at the
Ministry of Research and at the Regional Health Agency.
The GENES study protocol was approved by the local
Ethic Committee of the hospital of Toulouse (CHU
Toulouse/INSERM, file 1-99-48, February 2000) and the
national commission for data processing and freedoms
(N° 900165).
Principles of laboratory animal care (NIH publication
no. 85–23, revised 1985) were followed, as well those
of the European Union guidelines on animal labora-
tory care. Animals were kept in a pathogen-free bar-
rier facility and maintained in accordance with the
Institutional Animal Care and Use Protocol of the
University of Nice Sophia Antipolis and with appro-
priate National legislation concerning animal welfare.
All procedures were approved by the Animal Care
Committee of the Faculty of Medicine of the Nice
Sophia Antipolis University (Comité Institutionnel
d'Éthique Pour l'Animal de Laboratoire).
Results and discussion
Pro-apoptotic and atherogenic stimuli induce the
expression of s-RNYs in macrophages
To discover novel small RNAs expressed in human and
mouse apoptotic macrophages we performed a high-
throughput small RNA sequencing in primary macro-
phages stimulated with either STS or M-CSF withdrawal(Additional file 6: Tables S1 and Additional file 7:
Table S2). We observed that RNY-derived small RNAs
were among the most upregulated and expressed
small RNAs detected in human apoptotic macrophages
(Fig. 1a, Additional file 8: Figure S1 and Additional file 9:
Figure S2A, and Additional file 10: Table S3). This result
was also confirmed in mouse apoptotic macrophages
(Additional file 9: Figure S2B and Additional file 10:
Table S3), indicating that RNY processing into small
species is evolutionarily conserved. We found that
the RNY-derived small RNAs vary in length from ~24
to ~34 nt and map at the end of the stem regions of
RNYs (Additional file 8: Figures S1, Additional file 9:
Figure S2B and C). We refer to these small RNAs as
s-RNYs. RNY genes account for four copies in human
(RNY1, 3, 4, and 5) and two in mouse genomes (RNY 1
and 3), and their sequence is conserved in vertebrates
[30]. RNYs are characterized by extensive base-pairing of
the 5′ and 3′ regions and by the association with Ro60
and La/SSB [30]. Interestingly, only in human macro-
phages we detected many reads mapped on RNY pseudo-
genes. Indeed, in the human genome, the presence of 966
pseudogenes derived from the RNYs has been previously
reported, whereas they can be rarely found in mouse [31].
Therefore, the expression of different types of RNY frag-
ments in human apoptotic macrophages reflects the much
bigger copy number of RNYgenes and pseudogenes in hu-
man. Accordingly, detection of fragments derived from
the so-called RNY pseudogenes was previously observed
in human serum and plasma [32], thus suggesting that
they should be considered as belonging to a multicopy
gene family rather than pseudogenes. Northern blot,
quantitative RT-PCR (RT-qPCR), and high-throughput
RNA sequencing from 25–40 nt size selected RNA puri-
fied by polyacrylamide gel electrophoresis confirmed that
the expression of s-RNYs was induced in primary macro-
phages treated with different apoptotic stimuli (Fig. 1b,
Additional file 2: Figure S3A, B, and C, Additional file 11:
Table S4).
Although the mouse s-RNY1-5p have been previously
classified as piRNA (piRNABank, [33]) and the human
Fig. 2 s-RNY expression is induced in atherosclerotic areas and in smooth muscle foam cells. a RT-qPCR analysis of s-RNY1-5p in ApoE−/− aortic
arches and femoral arteries. The data were normalized by U2 snRNA and are presented as mean and standard deviation (n per group = 5).
b RT-qPCR analysis of the indicated s-RNYs in CRL 2797 cells (smooth muscle cells; left panel, n per group = 6), CRL 2181 cells (endothelial
cells; central panel, n per group = 7), primary myocardial cells (right panel, n per group = 3) incubated for 28 h with 0.25 μM thapsigargin in
combination with the indicated concentration of acetylated LDL and control. The data were normalized by U2 snRNA and are presented as
mean and standard deviation. Student’s t-test: *P <0.05, **P <0.01
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considered as belonging to an independent class of small
RNAs. Indeed, while s-RNYs are associated with Ro60
(Additional file 2: Figures S3D) [35] to form a ribonu-
cleoprotein complex of unknown function, miRNAs and
piRNAs associate with Argonaute 2 or Piwi, respectively,
to silence target RNAs [36].Fig. 3 s-RNYs are released in the extracellular milieu by foam cells and in t
of the indicated s-RNYs in the blood plasma of ApoE−/− (a) or Ldlr−/− (b) mice
diet. Data were normalized by using cel-miR-39 and are presented as mean
for (b)). c RT-qPCR analysis of the indicated s-RNYs from the medium of
analysis of the indicated s-RNYs from the medium of CRL 2797 cells (sm
combination with the indicated concentration of acetylated LDL and control.
standard deviation (n per group = 4). e RT-qPCR of s-RNY1-5p in the blood pl
by cel-miR-39 and are presented as mean and standard deviation (n per grouA number of lipids and lipoproteins associated with
atherosclerotic diseases conspires with ER stress to cause
macrophage apoptosis and progression of atherosclerotic
lesions [4]. To determine whether s-RNYs are induced
in macrophages stimulated with athero-relevant stimuli,
we treated BMDMs with oxLDL, alone or in presence of
the ER stessor Tg. Whereas low dose of oxLDL or Tghe peripheral blood of two mouse models for atherosclerosis. RT-qPCR
or control (wt). Mice were fed with either chow diet or high cholesterol
and standard deviation (n per group = 8 for (a) and n per group = 5
bone marrow-derived macrophages (n per group = 4). d RT-qPCR
ooth muscle cells) incubated for 28 h with 0.25 μM thapsigargin in
The data were normalized by cel-miR-39 and are presented as mean and
asma of CD68-hBcl-2 ApoE−/− or control (ApoE−/−). Data were normalized
p = 4). Student’s t-test: *P <0.05, **P <0.01
Fig. 4 (See legend on next page.)
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Fig. 4 Circulating s-RNY1-5p expression is induced in patients with CAD. a Box plot showing the expression in natural logarithmic scale of
circulating s-RNY1-5p in the derivation cohort composed by the serum of 43 coronary artery disease (CAD) patients versus 106 control individuals
(left panel). Data derived from RT-qPCR, normalized using cel-miR-39, and presented as mean and standard deviation. Receiver operating characteristic
(ROC) curve for predicting CAD with s-RNY1-5p was based on the RT-qPCR data of n = 149 (right panel). The area under the ROC curve is indicated.
b, c Box plots showing, in the derivation cohort (43 CAD patients and 106 control individuals), the expression of circulating s-RNY1-5p normalized with
the indicated reference genes, in linear scale (b) and natural logarithmic scale (c). d Pearson, Spearman, and interclass correlation coefficients among
the circulating s-RNY1-5p values normalized with the indicated reference genes. Student’s t-test: ***P <0.001
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agents together synergistically induced s-RNY expression
(Fig. 1c and Additional file 2: Figure S3E). Similar re-
sults were observed with acLDL (Additional file 2:
Figure S3F). We then tested whether different types
of fatty acids could also trigger s-RNY induction in
macrophages. Only saturated fatty acids, such as pal-
mitic acid and stearic acids, induced s-RNY expression
and this effect was increased markedly in presence of Tg
(Fig. 1d and Additional file 2: Figure S3G). Moreover, to
test whether the s-RNYs are induced in animal models for
atherosclerosis, we compared ApoE−/−, Ldlr−/−, and con-
trol mice. As shown in Fig. 1e,f, RT-qPCR from microdis-
sected aortic arches revealed that s-RNYs were
significantly upregulated in ApoE−/− and Ldlr−/− mice
compared to control, and that the HCD significantly in-
creased their expression. However, s-RNYs were not mod-
ulated in atheroprotected sites, such as femoral artery
(Fig. 2a), suggesting specificity for atherosclerotic lesions.
To assess the cellular origin, we measured the levels
of s-RNY expression in different cell types involved in
cardiovascular disease. Besides macrophages, we in-
vestigated endothelial cells, primary cardiomyocytes,
and SMCs. Among those cells, only SMCs showed a
significant increase of s-RNYs upon acLDL and Tg
stimulus (Fig. 2b).
Because s-RNYs have been found in significant
amounts in the blood [37], we compared s-RNY expres-
sion levels in the blood of ApoE−/−, Ldlr−/− and control
mice. As shown in Fig. 3a,b, RT-qPCR from blood
plasma revealed that s-RNYs were significantly upregu-
lated in ApoE−/− and Ldlr−/− mice compared to control,
and even more when mice were fed with a HCD. Con-
sistently with the results on cultured cells, a significant
upregulation of s-RNYs was observed in the medium of
both lipid-laden macrophages and SMCs (Fig. 3c,d). Im-
portantly, two main types of foam cells were described
in atherosclerotic lesions: those derived from macro-
phages and those derived from SMCs [38]. Unfortu-
nately, the contribution of these two cell types to the
total lesional foam cell population in atherosclerosis has
not been elucidated yet, mainly because lipid-laden
SMCs assume a macrophage-like phenotype [38]. There-
fore, to determine the role of macrophages as a source
of serum s-RNYs, we used the ApoE−/− mouse model inwhich the human isoform of the anti-apoptotic Bcl-2
gene was expressed only in macrophages under the
CD68 promoter [5]. This mouse model, here called
CD68-hBcl-2 ApoE−/−, is characterized by the dramatic
downregulation of the apoptosis in macrophages, ultim-
ately resulting in a significant reduction of the size of
atherosclerotic advanced lesions [5]. Importantly, our re-
sults indicate that circulating s-RNY expression was sig-
nificantly downregulated in CD68-hBcl-2 ApoE−/− mice
compared to the control ApoE−/− mice (Fig. 3e).
Altogether, these data identified apoptotic macrophage-
derived foam cells as the main source of s-RNYs in
atherosclerosis.
s-RNYs are upregulated in the serum of patients with
coronary artery disease (CAD)
Because changes in the level of circulating s-RNY ex-
pression were observed in different pathophysiological
processes, such as some types of cancer [37, 39], it is
conceivable that expression of circulating s-RNYs may
also be affected in atherosclerotic cardiovascular dis-
eases. To test this hypothesis, we measured the level of
serum s-RNY1-5p in the GENES study cohort [24], in-
cluding 43 male patients with stable CAD (cases) and
106 age-matched healthy men (derivation sub-cohort).
Average levels of circulating s-RNY1-5p, normalized
with the exogenous spike-in cel-miR-39, were signifi-
cantly lower in controls than in CAD patients (P <0.001;
Fig. 4a). The same results were observed upon
normalization with two endogenous small RNAs,
namely the miR-24 [21] or the RNU48 [22] (Fig. 4b,c),
indicating that our data were independent on the type
of normalizer used (Fig. 4d). We then validated this first
observation in an independent sub-cohort, including 220
CAD patients and 408 controls selected from the
GENES cohort (validation sub-cohort; Additional file 5:
Figure S4A).
Like microRNAs, s-RNYs are also strikingly stable in
cell culture medium compared to U6 snRNA (Fig. 5a),
and in human serum from CAD patients after incuba-
tion at room temperature for up to 24 h (Fig. 5b) or up
to eight cycles of freeze-thaw (Fig. 5c). Extracellular
microRNA stability is caused by their association with
protein complexes, microvesicles, exosomes, apoptotic
bodies, or lipoproteins [40]. Plasma s-RNYs have been
Fig. 5 s-RNY1-5p is stable in extracellular environment. a Northern blot analysis showing the stability of s-RNY1-5p and U6 snRNA in the medium
of bone marrow-derived macrophages stimulated with 1 μM of staurosporine at the indicated time points. Total RNA was isolated from the
medium. b, c RT-qPCR analysis from three coronary artery disease patients showing the stability of s-RNY1-5p in the serum in either prolonged
room temperature incubation (b) or different cycles of freeze-thaw as indicated (c). Data were normalized by using the synthetic non-mammalian
cel-miR-39, which was added to the samples before the RNA extraction. Each ΔCt (corresponding to Cts-RNY1-5p-Ctcel-miR-39) is the average of three
technical replicates
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mass between 100 and 300 kDa [32]. Similarly, serum s-
RNY4-5p was upregulated in 45 CAD patients compared
to 45 controls from the same study cohort (Fig. 6a,b),
whereas s-RNY3-5p was undetectable. Therefore, these
data indicate that circulating s-RNYs are induced in
CAD patients and may be considered as novel bio-
markers for CAD status.Fig. 6 Circulating s-RNY4-5p expression is induced in patients with corona
logarithmic scale of circulating s-RNY4-5p in the serum of CAD patient
RT-qPCR were normalized using cel-miR-39, and presented as mean an
curve for predicting CAD with s-RNY4-5p. The ROC curve was construc
under the ROC curve is given and 95 % confidence interval was indicaWe then compared s-RNY1-5p expression levels with
cardiovascular risk factors or markers within the cohort
study to assess its value as a novel biomarker. In Table 1,
we report metabolic and clinical variables, including
serum sRNY1-5p levels, of the whole case–control co-
hort (derivation and validation sub-cohorts pulled to-
gether, P <0.001; Fig. 7a,b). Briefly, increased prevalence
of classical risk factors was recorded in CAD patients:ry artery disease (CAD). a Box plot showing the expression in natural
s (n = 45) versus control individuals (CTL, n = 45). Data derived from
d standard deviation. b Receiver operating characteristic (ROC)
ted using s-RNY4-5p based on the RT-qPCR data (n = 90). The area
ted in square brackets. Student’s t-test: ***P <0.001
Fig. 7 (See legend on next page.)
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Fig. 7 s-RNY1-5p is an independent diagnostic biomarker for coronary artery disease (CAD). a Box plots showing the expression in natural
logarithmic scale of circulating s-RNY1-5p in the serum of CAD patients (n = 263) versus control individuals (CTL, n = 514). Data derived from
RT-qPCR were normalized using cel-miR-39, and presented as mean and standard deviation. b Receiver Operating Characteristic (ROC) curve for
predicting CAD with s-RNY1-5p. The ROC curve was constructed using s-RNY1-5p based on the RT-qPCR data (n = 777). The area under the ROC
curve is given and 95 % confidence interval was indicated in square brackets. The diagonal line indicates a test with an area under the ROC curve
of 50 %; P <0.0001. c RT-qPCR analysis of the indicated s-RNYs in bone marrow-derived macrophages incubated for 24 h with the indicated
concentrations of different statins. The data were normalized by U2 snRNA and presented as mean and standard deviation (n per group = 3).
d ROC, in blue the curve for classical risk factors and markers (hypertension, dyslipidemia, diabetes, smoking, waist circumference, ankle-arm index,
ApoA-I, and hs-CRP), in red the same classical risk factors and markers with s-RNY1-5p. The ROC curve was constructed using s-RNY1-5p
expression based on the RT-qPCR data (n = 777). The area under the ROC curve is given and 95 % confidence interval was indicated in
square brackets. Student’s t-test: ***P <0.001
Table 2 Relationships between s-RNY1-5p and classical





Age (years) −0.07 (0.10) −0.09 (0.14)
School (years of schooling) 0.01 (0.88) −0.05 (0.39)
Alcohol (g/day) −0.12 (0.008) −0.04 (0.50)
Tobacco consumption number (pack/year) 0.04 (0.50) 0.14 (0.03)
Levels of physical activity −0.01 (0.88) −0.04 (0.50)
Waist (cm) −0.09 (0.04) −0.02 (0.80)
Body mass index (kg/m2) −0.07 (0.14) −0.03 (0.63)
Total cholesterol (g/L) 0.07 (0.11) 0.11 (0.09)
HDL-cholesterol (g/L) −0.03 (0.53) −0.02 (0.82)
LDL-cholesterol (g/L) 0.09 (0.05) 0.12 (0.06)
Triglyceride (g/L) 0.03 (0.52) 0.01 (0.90)
ApoA-I (g/L) −0.09 (0.04) −0.08 (0.17)
ApoB (g/L) 0.18 (<0.001) 0.18 (0.003)
Lipoprotein (a) (g/L) 0.04 (0.39) 0.07 (0.24)
hs-CRP (mg/L) 0.16 (<0.001) 0.14 (0.03)
Gamma glutamyl transferase (IU/L) 0.04 (0.41) 0.11 (0.09)
Fasting glucose (mmol/L) 0.06 (0.22) −0.04 (0.54)
Serum insulin (UI/L) −0.07 (0.14) −0.02 (0.81)
HOMA-IR −0.05 (0.24) −0.05 (0.46)
Systolic blood pressure (mmHg) −0.01 (0.74) −0.08 (0.19)
Resting heart rate (beat/mn) 0.04 (0.42) 0.03 (0.64)
Spearman rank correlation coefficients (P value)
ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; hs-CRP, High sensitive
C-reactive protein; HOMA-IR, Homeostatic model assessment-insulin resistance
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cholesterol >2.50 g/L), and smoking habits. BMI and
waist circumference were higher in CAD-affected than
in control individuals, while educational level and phys-
ical activity were lower. Averages of alcohol consump-
tion were not significantly different between cases and
controls. However, alcohol patterns were different, with
a higher percentage of moderate alcohol consumption
(<40 g/day) in controls and, conversely, a higher
percentage of both abstinent and excessive drinkers
(≥40 g/day) in cases. Among metabolic markers, total
cholesterol or LDL-cholesterol were lower in CAD in-
dividuals, reflecting effects of lipid-lowering drugs in
patients. However, CAD individuals displayed hyper-
glycemia, higher levels of triglycerides and lipoprotein (a),
increased CRP, and lower HDL markers. Altogether,
48.5 % of CAD individuals had features of metabolic
syndrome, according to the National Cholesterol
Education Program’s Adult Treatment Panel III report
definition, versus 17.7 % of control subjects. Trans-
formation of s-RNY1-5p levels in the whole case–control
cohort into its exp1/7 derivative yielded normal distribu-
tion and was further used for statistics (Additional file 5:
Figure S4B and C). Spearman rank correlation coefficients
between the levels of serum s-RNY1-5p and metabolic
parameters or cardiovascular risk markers were calcu-
lated (Table 2). In CAD patients (n = 263) and control
individuals (n = 514), serum s-RNY1-5p was positively
correlated to the pro-atherogenic apoB-containing li-
poproteins and with an inflammatory condition, as
documented by an elevated hs-CRP. In controls,
negative correlations were found with the level of
atheroprotective apoA-I and with alcohol consump-
tion, whereas a positive correlation was found with
atherogenic LDL-cholesterol. Age, glycemic parame-
ters, and some environmental factors, such as physical
activity and school duration, were not associated with
s-RNY1-5p. No statistical interaction could be found
between, on the one hand, the coronary status and,
on the other hand, hs-CRP and apoB levels regarding
s-RNY1-5p levels (Table 3), indicating that the associationof s-RNY1-5p with CAD status was independent of the
concentration of those two markers. The independency
between the expression levels of serum s-RNY1-5p and
hs-CRP was also validated in a group of 17 male individ-
uals with blood infection originated from different entry
portals: lung, bone, cutaneous, digestive, and urinary track
(Additional file 4: Table S5). Comparisons were made with
35 age-matched controls from the GENES study. Al-
though, both sRNY1-5p (P <0.02) and hs-CRP (P <0.001)
Table 3 s-RNY1-5p level according to high sensitive C-reactive protein (hs-CRP) levels, apolipoprotein B (ApoB) levels, statin therapy,
and fibrate therapy and case–control (CC) status
CRP (mg/L) CC (s-RNY1-5p)1/7 CC effect hs-CRP effect CC × hs-CRP interaction
<6 Case (n = 121) 1.30 (0.17) 0.001 0.03 0.72
≥6 Case (n = 142) 1.34 (0.18)
<6 Control (n = 449) 0.95 (0.18)
≥6 Control (n = 65) 0.98 (0.20)
ApoB (g/L) CC (s-RNY1-5p)1/7 CC effect ApoB effect CC × ApoB interaction
<1.02 Case (n = 115) 1.30 (0.18) 0.001 0.001 0.79
≥1.02 Case (n = 148) 1.35 (0.17)
<1.02 Control (n = 200) 0.92 (0.19)
≥1.02 Control (n = 314) 0.97 (0.19)
Statin therapy CC (s-RNY1-5p)1/7 CC effect statin effect CC × statin interaction
No Case (n = 115) 1.34 (0.18) 0.001 0.15 0.78
Yes Case (n = 148) 1.31 (0.18)
No Control (n = 428) 0.95 (0.19)
Yes Control (n = 86) 0.93 (0.20)
Fibrate therapy CC (s-RNY1-5p)1/7 CC effect fibrate effect CC × fibrate interaction
No Case (n = 242) 1.33 (0.17) 0.001 0.21 0.46
Yes Case (n = 21) 1.28 (0.19)
No Control (n = 472) 0.95 (0.19)
Yes Control (n = 42) 0.94 (0.18)
Table 4 Association of s-RNY1-5p with coronary artery disease
(case–control study)
Models with Q1 + Q2 Q3 Q4
OR (95 % CI) OR (95 % CI) OR (95 % CI)
s-RNY1-5p 1 15.4 (8.5–27.8) 204.7 (102.3–409.6)
s-RNY1-5p a 1 18.0 (7.9–40.8) 206.7 (76.2–560.5)
Quartiles for s-RNY1-5p: 0.47, 1.62, 4.70
Quartiles Q1 and Q2 were grouped together since there was only one case in
Q1 (patients)
a Adjusted for waist circumference, tobacco consumption (pack/year), ankle-arm
index, hypertension, diabetes, hs-CRP (log), ApoA-I, ApoB, total alcohol
consumption, statin drug and fibrate drug
OR, Odds ratio; 95 % CI, 95 % Confidence intervals
Repetto et al. BMC Medicine  (2015) 13:259 Page 15 of 19levels were elevated in infected patients, sRNY1-5p induc-
tion was moderate compared to that found in CAD pa-
tients, conversely, hs-CRP levels were far higher in
infected subjects. Moreover, no significant correlation was
found between both markers (Spearman rank correlation
coefficient: 0.15, P = 0.56). Hence, we concluded that,
whereas CRP is an unambiguous marker for systemic
inflammation, sRNY1-5p might be more specifically retali-
ated to the local inflammatory process occurring in ath-
erosclerotic lesions.
The association of s-RNY1-5p with CAD was also in-
dependent of lipid-lowering treatments (statins and
fibrates, Table 3). We further investigated the effects of
four different statins, namely fluvastatin, simvastatin,
lovastatin, and pravastatin, on the s-RNY expression in
macrophages. As shown in Fig. 7c, none of the statins
used significantly impacted on s-RNY expression in
BMDMs, confirming that changes on serum s-RNY ex-
pression are independent from treatments with statins.
To further explore the association with CAD, a ROC
curve was constructed using s-RNY1-5p (Fig. 7b,
AUC = 93.6 [91.9–95.3]) together with classical cardiovas-
cular risk factors, including hypertension, dyslipidemia,diabetes, smoking, waist circumference, ankle-arm index,
ApoA-I, and hs-CRP (basic model in Fig. 7d, AUC = 92.8
[90.8–94.8]). As shown in Fig. 7d, the resultant ROC curve
displays a greater AUC compared to the basic model
(AUC= 97.9 [97.1–98.7], P <0.001 for the difference).
Moreover, quartile ranking of s-RNY1-5p was performed
and the odds ratios with 95 % confidence intervals were
determined (Table 4). In these models, higher levels
of s-RNY1-5p were strongly and significantly associ-
ated with CAD. In multivariate analyses, this association
Repetto et al. BMC Medicine  (2015) 13:259 Page 16 of 19was maintained when adjustments were performed on
cardiovascular risk factors, markers, or factors associated
with s-RNY1-5p, including waist circumference, tobacco
consumption (pack/year), ankle-arm index, hypertension,
diabetes, hs-CRP, apoA-I, apoB, alcohol consumption, and
lipid-lowering treatments.
Altogether, these results evidence a strong positive
independent association between the levels of serum
s-RNYs and CAD risk, overall supporting the hypoth-
esis that s-RNY1-5p is an independent signature of
CAD, which can improve CAD diagnosis and risk
stratification.
Conclusions
In conclusion, the present study demonstrates the gener-
ation of RNY-derived small RNAs, namely s-RNYs, in
macrophages incubated with pro-apototic and athero-
genic stimuli. Significantly increased levels of s-RNYs areTable 5 Comparative analysis between s-RNY1-5p and selected coro
Normalization by cel miR-39 2-ΔΔCt in CAD 2-ΔΔCt in CTL R
sRNY1-5p 12.15861132 1.506803056 0
miR17 0.804077414 0.920930566 0
miR92a 4.91098005 0.976527138 0
miR126 2.592316951 1.265612624 0
miR133 4.765530301 1.095526208 0
miR145 4.239215843 0.979840396 0
miR155 8.677582108 1.039014581 0
miR208a 5.554050756 1.058798935 0
Normalization by RNU48 2-ΔΔCt in CAD 2-ΔΔCt in CTL R
sRNY1-5p 13.95354052 1.069518668 0
miR17 1.084053274 0.949856557 0
miR92a 1.20101817 1.033002128 0
miR126 1.44021571 1.072261942 0
miR133 1.334960926 1.126558473 0
miR145 1.52987889 0.939525323 0
miR155 0.891246591 1.064118053 0
miR208a 0.247755721 1.009457364 0
Normalization by miR-24 2-ΔΔCt in CAD 2-ΔΔCt in CTL R
sRNY1-5p 11.26524945 0.975729203 0
miR17 1.509090429 0.934815204 0
miR92a 2.551324286 0.952726947 0
miR126 1.754084858 1.200874169 0
miR133 2.155706321 0.928731186 0
miR145 3.099747057 1.041255052 0
miR155 1.828043362 1.008436566 0
miR208a 1.334878917 1.120233854 0
CAD, Coronary artery disease; CTL, Control; ROC, Receiver operating curveobserved in the blood of mouse models for atheroscler-
osis and CAD patients, in which they are independently
associated with CAD risk factors and markers.
In the future, s-RNYs could be used as independent
diagnostic biomarkers for CAD to better evaluate cardio-
vascular risk, when combined into a “multimarker” score
[41]. Furthermore, measurement of circulating s-RNY
levels would be a valuable companion diagnostic to moni-
tor foam cell apoptosis during atherosclerosis pathogen-
esis and to evaluate a patient’s responsiveness to future
therapeutic strategies aiming to attenuate apoptosis in
foam cells in advanced atherosclerotic lesions.
Many publications previously showed that other non-
coding RNAs, mostly miRNAs, can be potentially used
as biomarkers of cardiovascular disorders [42]. miRNAs
and s-RNYs share the same advantages, including high
sensitivity and specificity detection, the fact that a single
sample can be used for the detection of many smallnary artery disease-associated miRNAs in the derivation cohort
OC Area P value Std. Error 95 % Confidence interval
.919 <0.0001 0.02286 0.8742–0.9639
.5687 0.1898 0.0501 0.4705–0.6669
.5919 0.07926 0.05539 0.4833–0.7005
.6784 0.0006643 0.04854 0.5832–0.7735
.5965 0.06534 0.05355 0.4915–0.7015
.5083 0.8735 0.05351 0.4034–0.6132
.6255 0.01659 0.05367 0.5203–0.7307
.7246 <0.0001 0.0484 0.6297–0.8195
OC Area P value Std. Error 95 % Confidence interval
.8341 <0.0001 0.0442 0.7475–0.9208
.5428 0.414 0.05115 0.4425–0.6431
.7865 <0.0001 0.03945 0.7092–0.8639
.509 0.8636 0.06102 0.3894–0.6286
.5608 0.2459 0.05328 0.4563–0.6652
.749 <0.0001 0.04181 0.6670–0.8310
.527 0.6064 0.05249 0.4241–0.6299
.6772 0.0007879 0.04678 0.5855–0.7689
OC Area P value Std. Error 95 % Confidence interval
.9382 <0.0001 0.0236 0.8919–0.9845
.6605 0.002226 0.04591 0.04591
.767 <0.0001 0.04154 0.6856–0.8484
.5595 0.2568 0.05284 0.4559–0.6631
.5996 0.05769 0.05292 0.4958–0.7033
.7506 <0.0001 0.04349 0.6653–0.8359
.5143 0.7853 0.05613 0.4043–0.6243
.6398 0.008176 0.0532 0.5355–0.7441
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very high stability, and serum abundance [43]. However,
our data indicate that s-RNY1-5p correlates much more
with a CAD status compared to other CAD-specific
miRNAs, including miR-17, miR-92a, miR-126, miR-133,
miR-145, miR-155, and miR-208 (Table 5), indicating the
potential biomedical implications of s-RNY measure-
ment as a diagnostic tool. Future epidemiological studies
on perspective cohorts will provide useful information
on prognostic values of serum s-RNY expression. In
short, our work represents a step forward toward a crit-
ical assessment of circulating small non-coding RNAs
(but not only miRNAs) as biomarkers for cardiovascular
diseases.
Accession numbers
Experimental datasets have been deposited in the
NCBI Gene Expression Omnibus (GEO) [44] under
the Series record numbers: GSE63802. Link to the
direct access: [45].
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